BPC-157 · TB-500 (5 mg + 5 mg) (Blend)

BPC-157 is classified as a synthetic gastric-pentadecapeptide research compound. The sequence was originally derived from a larger protein identified in gastric extracts, and the 15-residue synthetic version has become a widely used reference compound in cellular-pathway research and nitric oxide signalling research.

Laboratory research studies have characterized BPC-157 as a stable research peptide in acidic conditions, a property that distinguishes it from many other bioactive research peptides. This stability profile has made it a useful tool in laboratory research studies of gastric-tissue research, where peptide integrity under acidic conditions is an important methodological consideration.

Mechanistic research has investigated BPC-157 engagement with vascular endothelial pathways, including VEGFR2 signalling research and the Akt-eNOS axis. Additional research models have examined interaction with the broader nitric oxide system, Src-Cav-1-eNOS signalling, and inflammatory-pathway research. This positioning at the intersection of nitric oxide signalling research, endothelial cellular-process research, and gastric-tissue research has made BPC-157 a research peptide of considerable interest in laboratory research studies of pentadecapeptide pharmacology and integrated cellular-pathway signalling.

Thymosin beta-4 is a 43-amino-acid acidic peptide first isolated from thymic tissue and subsequently identified as one of the most abundant intracellular actin-sequestering peptides in mammalian cell types. It functions as a 1:1 G-actin-binding research peptide and contributes to the maintenance of a pool of monomeric actin available for rapid cytoskeletal reorganization in cellular research models.

TB-500 is supplied as a synthetic full-length analog of the thymosin beta-4 sequence, allowing laboratory research studies to use a defined reference compound for actin-binding research and cytoskeletal dynamics research. The sequence retains the central LKKTET actin-binding motif (residues 17-22), which has been mapped through mutational and structural research as the principal contact region with G-actin in research models.

This positioning at the intersection of cytoskeletal dynamics research, cellular-process research, and structure-activity research has made TB-500 an experimental research compound of considerable interest in laboratory research studies of actin-binding pharmacology, endothelial cellular-process research, and comparative thymosin beta-4 fragment research.

1. VEGFR2 Signalling Research

BPC-157 has been investigated in laboratory research studies for engagement with vascular endothelial growth factor receptor-2 (VEGFR2) signalling. Mechanistic research models indicate that BPC-157 modulates VEGFR2 expression and internalization, supporting investigations into endothelial cellular-process research and vascular-pathway research (Hsieh et al., 2017, Journal of Molecular Medicine).

2. Akt-eNOS Axis and Nitric Oxide Signalling Research

Laboratory research studies have characterized BPC-157 engagement with the Akt-endothelial nitric oxide synthase (eNOS) axis. This signalling research is associated with nitric oxide production in endothelial research models and has been investigated as a downstream consequence of VEGFR2 modulation in cellular-pathway research.

3. Src-Cav-1-eNOS Pathway Research

Research models have also characterized BPC-157 engagement with the Src-Caveolin-1-eNOS pathway. Mechanistic research indicates that BPC-157 enhances phosphorylation of Src, Cav-1 and eNOS and reduces Cav-1-eNOS binding in vascular research models, supporting investigations into nitric oxide signalling research independent of canonical VEGFR2 input (Hsieh et al., 2020, Scientific Reports).

4. Gastric-Tissue Research Models

Laboratory research studies have investigated BPC-157 stability in acidic conditions and its engagement with gastric-tissue research models. These investigations support research on pentadecapeptide pharmacology and cellular-pathway research relevant to gastric-tissue research.

Research Applications

Conclusion

BPC-157 is a synthetic 15-residue gastric-pentadecapeptide research compound that engages VEGFR2 signalling, the Akt-eNOS axis, and the Src-Cav-1-eNOS pathway in research models. Its combination of acidic-condition stability and characterized engagement with nitric oxide signalling research makes it a valuable investigational laboratory peptide for laboratory research studies in cellular-pathway research, endothelial cellular-process research, and gastric-tissue research models.

1. Actin-Binding and Cytoskeletal Dynamics Research

TB-500 engages monomeric G-actin in a 1:1 stoichiometry through its central LKKTET actin-binding motif. In laboratory research studies, this interaction sequesters G-actin and modulates the equilibrium between monomeric and filamentous actin populations, supporting investigations into cytoskeletal dynamics research and cellular-process research models.

2. Cellular-Process Signalling Research

TB-500 has been investigated in cellular research models for its interaction with endothelial and epithelial cell migration pathways. Research models indicate that the full-length thymosin beta-4 sequence engages cellular-process signalling research relevant to cellular-pathway research and structure-activity research with discrete actin-binding fragments such as LKKTETQ.

3. Inflammatory-Pathway Research

Laboratory research studies have examined how TB-500 modulates inflammatory-pathway research markers in cellular and animal research models. These investigations are relevant to cytokine-signalling research and comparative research on thymosin beta-4 active-site fragments.

4. Structure-Activity Research

By supplying the full-length 43-residue sequence, TB-500 enables comparative research alongside discrete fragments such as the heptapeptide LKKTETQ (residues 17-23). This supports structure-activity research investigating how isolated actin-binding domains compare to the parent peptide in actin-binding research and cellular-process research models.

Research Applications

Conclusion

TB-500 is a synthetic full-length thymosin beta-4 research peptide that engages monomeric G-actin through its central LKKTET motif and supports laboratory research studies of cytoskeletal dynamics research, cellular-process research, and inflammatory-pathway research. Its defined sequence and 1:1 actin-binding profile make it a valuable reference compound for laboratory research studies of actin-binding pharmacology and comparative research with thymosin beta-4 active-site fragments.